New analyses suggest Alzheon’s therapy may pro
Author: Michael
The startup is betting that the future of longev
Eisai and Biogen presented data at the Alzheimer’s Association International Conference 2026 in London showing that a lecanemab subcutaneous autoinjector (LEQEMBI) produced exposure, efficacy and safety comparable to the approved intravenous initiation regimen in people with early Alzheimer’s disease. According to the company, once-weekly 500 mg subcutaneous administration demonstrated bioequivalence to the IV initiation regimen (10 mg/kg every two weeks) with an exposure ratio of 104% (90% confidence interval 99.1%–109%) and consistent exposure across body weight quartiles. The companies claim that amyloid reduction measured by PET, clinical efficacy on CDR-SB and incidence of ARIA-E were driven by lecanemab exposure rather…
Cognito Therapeutics presented exploratory cerebr
At the Alzheimer’s Association International Co
NeuroTherapia will present data from its recently
Indiana University and PharmatrophiX presented a
Aeon welcomed the establishment of the Dubai Long
Eisai presented data at the Alzheimer’s Associa
The New England Journal of Medicine published a p